ME   $0.5236  4.97% Market Closed

23andMe Holding Co
Last Events:

2023-08-09 Trend pattern changed from расходящийся клин с наклоном вниз to нисходящий треугольник.

2023-08-09 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the oversold territory and it grows. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-05 Signal in MACD changed from bearish reversal to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: down-crossing the middle level.

2023-08-05 Trend Power changed from medium strength to strong.

2023-08-04 Signal in Stochastic changed from bearish weakening to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-08-04 Signal in MACD changed from bullish weakening to bearish reversal. Oscillator MACD is in the positive territory it crossed the signal line from the top and falls. These factors mean that the market confirms the end of the upward trend. Last signal: main and signal line crossing.


Current temperature: 13.73
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 2
Target Price Mean 1.24
Mean unverified/preliminary 1.24 / 1.24
Target Price Low / High 0.47 / 2.00
Median / STD DEV 1.24 / 1.08
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy ActivelyBuy ActivelyBuy
rsi ActivelyBuy ActivelyBuy ActivelyBuy
macd None ActivelyBuy None
stoch ActivelyBuy None None
ma20 None ActivelyBuy ActivelyBuy
ma50 ActivelyBuy None None
ma100 ActivelyBuy ActivelyBuy ActivelyBuy
Candlestick PatternNov. 13, 2023 Bullish Three Inside Up - pattern is a made up of three candlesticks. Big black candlestick appears on the first day in a downtrend. The second day body is engulfed by the body of the first day. A white candlestick on the third day with a higher close than the second day. Considered to be a bullish reversal pattern.
ISIN US90138Q1085
ceo Ms. Anne Wojcicki
Website https://www.23andme.com
23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.